Core D: Nonhuman Primates

核心 D：非人类灵长类动物

基本信息

批准号：
10425029
负责人：
Francois J Villinger
金额：
$ 152.77万
依托单位：
UNIVERSITY OF WASHINGTON
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-02 至 2025-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10425029
关键词：
2019-nCoV Abate Adjuvant Animal Model Animals Antibodies Antigens Antiviral Therapy B-Lymphocytes Brazil COVID-19 COVID-19 pandemic COVID-19 vaccine Cells Cessation of life Chiroptera Clinic Collaborations Coronavirus Coronavirus Infections Data Development Disease Distant Economics Epidemic Epitopes Evaluation Event Evolution Experimental Designs Formulation Funding Future Generations Genome Goals Herd Immunity Human Immune Immune response Immunization Immunologics India Lead Macaca fascicularis Middle East Respiratory Syndrome Modeling Mosaicism Patients Performance Persons Phase Phase II Clinical Trials Plasma Cells Plasmablast Population Primates Process Rodent SARS-CoV-2 B.1.351 Sampling Sarbecovirus Scaffolding Protein Secure Severe Acute Respiratory Syndrome South African South American Specificity Structure Surface T-Lymphocyte Testing Time Translating Vaccinated Vaccination Vaccine Design Vaccines Validation Variant Viral Virulence Virus Work Zoonoses base betacoronavirus vaccine clinically relevant coronavirus vaccine design economic cost experimental study fitness flexibility improved mortality mutant nanoparticle neutralizing antibody nonhuman primate novel novel coronavirus pandemic disease pathogen post SARS-CoV-2 infection prevent programs protective efficacy receptor binding response sample collection transmission process vaccine candidate vaccine efficacy vaccine trial virology ward zoonotic coronavirus

项目摘要

PROJECT SUMMARY – CORE D: NONHUMAN PRIMATES COVID-19 has served as a wake-up call regarding the ability of a pathogen to rapidly spread to all confines of the world and establish a lasting pandemic, with considerable disease, death, and economic losses. While preceded by SARS and MERS, COVID-19 turned out markedly more contagious, and for all practical purposes impervious to existing antiviral therapies, leading to extensive spreading as well as giving rise to immunologically distinct mutants with higher transmission fitness. Moreover, COVID-19 is the third coronavirus zoonosis in the 21s century that has been threatening humans, and wildlife and various species of bats in particular have been demonstrated to harbor several other coronaviruses susceptible to transmitting and generating additional epidemics/pandemics. The overarching goal of this program is to design and develop both pan-sarbecovirus and pan-betacoronavirus vaccines to preemptively ward off such widely disseminated zoonotic transmission, using a structure-based immunogen design approach. The goal of Core D (Nonhuman Primates, Villinger) will be to evaluate the most promising immunogens initially screened in rodents, combined with clinically relevant adjuvants to elicit protective humoral and cellular immune responses in cynomolgus macaques, as a model more closely related to humans. The Core will be responsible for conducting the nonhuman primate experiments, from animal procurement, animal characterization, satisfying regulatory requirements, planning and execution of the primate immunizations and sample collections, processing, storage and distributions to collaborating partners of the Program. Results of these studies are expected to iteratively refine and optimize immunogen/adjuvant formulations and provide data leading to the validation of a pan sarbecovirus and a pan betacoronavirus vaccine to be translated to the clinic.

项目摘要 - 核心D：非人类灵长类动物 Covid-19已成为有关病原体快速扩散到所有范围的能力的警钟世界并建立了持久的大流行，具有可考虑的疾病，死亡和经济损失。尽管在SARS和MERS之前，Covid-19结果显着具有传染性，出于所有实际目的不受现有的抗病毒疗法的不渗透，导致广泛扩散并引起具有较高传播适应性的免疫学不同突变体。此外，Covid-19是第三个冠状病毒 21世纪的动物下降一直在威胁人类，野生动植物和各种蝙蝠中的各种蝙蝠已被证明携带其他几个冠状病毒易受传输和产生其他情节/大流行。该计划的总体目标是设计和开发 Pan-sarbecovirus和Pan-Betacoronavirus疫苗都可以预先阻止如此广泛的传播使用基于结构的免疫原设计方法的人畜传播。核心D（非人类灵长类动物，维林格）的目标是评估最有希望的免疫原子在啮齿动物中筛选，并结合临床相关的调节器，以引起受保护的体液和细胞膀胱猕猴中的免疫反应是与人类更紧密相关的模型。核心将是负责从动物采购，动物进行非人类灵长类动物实验表征，满足监管要求，主要免疫的计划和执行示例收集，处理，存储和分布，向计划的合作伙伴进行合作。结果这些研究有望迭代完善并优化免疫原/辅助配方，并提供导致PAN SARBECOVIRUS和PAN BETACORONAVIRUS疫苗验证的数据将转换为诊所。